ROCHESTER, N.Y., March 28 /PRNewswire/ -- Integrated Nano-Technologies
(INT) announced that in a collaborative test with the U.S. Army Edgewood
Chemical Biological Center, INT successfully demonstrated proof of concept for
INT's novel technology platform (BioDetect(TM)) for the detection of
biological agents. A recently released test report details how the technology
successfully detected anthrax DNA.
The BioDetect(TM) system will integrate DNA and microelectronics into a
field portable system. Since it does not require complicated DNA amplification
technology, results will be obtained more rapidly, with less training and
under more environmentally adverse conditions than with other approaches.
"This successful collaborative test of the BioDetect(TM) technology is a
key step in the development of this novel system," said Doyle Hill, Vice
President and Chief Operating Officer of INT. "We are extremely encouraged by
the performance of our technology in an external setting. We are planning
additional testing with the Army in the near future."
The BioDetect(TM) system will be a fully automated, portable,
non-amplified nucleic acid identification system that will be able to
accurately detect the presence of biological agents, such as SARS, anthrax and
smallpox, in as little as 20 minutes.
About INT's Technology
Integrated Nano-Technologies' core technology is a unique integration of
molecular biology, chemistry and microelectronics that facilitates the
development of technically advanced detection systems and other devices.
Biological agent identification is based on the ability of DNA probes on a
microchip to attract and bind to specific sequences in the DNA of a target
organism. DNA is extracted from a sample and passed over a sensor, where it
attaches to the organism-specific probes. The attached strands are metalized
through a chemical process, producing a strong electrical signal for computer
The BioDetect(TM) platform consists of an electronic analyzer and
single-use, disposable test cards. Unlike other detection systems,
BioDetect(TM) technology does not depend on DNA amplification by polymerase
chain reaction (PCR), but will provide comparable detection capability.
About Integrated Nano-Technologies, LLC
Rochester, NY-based Integrated Nano-Technologies, LLC is a leading
innovator in portable, electronic, biological agent identification technology.
Built around the BioDetect(TM) platform, INT's devices are highly portable and
use disposable test cards to test field samples for numerous biological
agents, including anthrax. Future developments of the platform may include
clinical and veterinary diagnostics, taggants and food safety applications.
For more information about Integrated Nano-Technologies, call 585-334-0170 or
visit INT's Web site at http://www.integratednano.com.
This press release contains forward-looking statements that are based upon
our current expectations and speak only as of the date hereof. Our actual
results may differ materially and adversely from those expressed in any
forward-looking statements as a result of various factors and uncertainties,
including our ability to successfully develop products, rapid technological
change in our markets, changes in demand for our future products, legislative,
regulatory and competitive developments and general economic conditions. We
undertake no obligation to revise or update publicly any forward-looking
statements for any reason.
SOURCE Integrated Nano-Technologies, LLC